OSLO, Norway, April 29, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light ...

SAN DIEGO & REHOVOT, Israel, April 25, 2025--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, will present data from an abstract describing the ...

A polyp is an abnormal mass of tissues arising from the mucous membrane of organs, including the bladder. Some bladder tumors ...

Nucleix to Present Data Showcasing Performance and Clinical Utility of Bladder EpiCheck® Monitoring in Non-Muscle Invasive Bladder Cancer (NMIBC) Recurrence at AUA 2025 Data demonstrates utility ...

OSLO, Norway, May 7, 2024 /PRNewswire/ --Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the AUA 2024: the ...

Among 1104 men at least 45 years old who were undergoing treatment for benign prostatic hyperplasia and had symptoms of overactive bladder, 538 received 75 mg of vibegron and 542 received a placebo.

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light Cystoscopy (BLC®), notably its impact on ...